Literature DB >> 22296117

Differential expression of forkhead box M1 and its downstream cyclin-dependent kinase inhibitors p27(kip1) and p21(waf1/cip1) in the diagnosis of pulmonary neuroendocrine tumours.

Seung Yeon Ha1, Chang Hun Lee, Hee Kyung Chang, Sunhee Chang, Kun Young Kwon, Eun Hee Lee, Mee Sook Roh, Boram Seo.   

Abstract

AIMS: Pulmonary neuroendocrine (NE) tumours represent a spectrum of phenotypically distinct entities with different biological behaviours. Difficulties in classifying these tumours are frequently encountered in clinical practice. Forkhead box M1 (FoxM1) is essential for the development of various cancers and is a proliferation-specific transcription factor that regulates transcription of cell cycle genes, including cyclin-dependent kinase inhibitors p27(kip1) and p21(waf1/cip1) . This study was performed to determine the utility of FoxM1, p27(kip1) and p21(waf1/cip1) as immunomarkers for subtyping pulmonary NE tumours. METHODS AND
RESULTS: FoxM1, p27(kip1) and p21(waf1/cip1) expression was evaluated by immunohistochemistry in 60 pulmonary NE tumours [19 typical carcinoids (TCs), six atypical carcinoids (ACs), 17 large cell neuroendocrine carcinomas (LCNECs) and 18 small cell lung cancers (SCLCs)]. The frequencies of FoxM1 and p21(waf1/cip1) expression were significantly different between TCs and ACs (each P = 0.009), and those of FoxM1 and p27(kip1) expression were significantly different between LCNECs and SCLCs (P = 0.012 and P = 0.002, respectively). The combined FoxM1((-)) /p21(waf1/cip1(-)) and FoxM1((+)) /p27(kip1(high)) phenotypes had the best diagnostic accuracy for distinguishing TCs from ACs, and SCLCs from LCNECs, respectively.
CONCLUSIONS: FoxM1, p27(kip1) and p21(waf1/cip1) showed distinct immunoreactivity according to histological subtype, which may be of value as an ancillary test in the differential diagnosis of pulmonary NE tumours.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22296117     DOI: 10.1111/j.1365-2559.2011.04137.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  9 in total

1.  Inactivation of FoxM1 transcription factor contributes to curcumin-induced inhibition of survival, angiogenesis, and chemosensitivity in acute myeloid leukemia cells.

Authors:  Jing-Ru Zhang; Fei Lu; Ting Lu; Wen-Hao Dong; Peng Li; Na Liu; Dao-Xin Ma; Chun-Yan Ji
Journal:  J Mol Med (Berl)       Date:  2014-09-03       Impact factor: 4.599

2.  Prognostic Significance of Forkhead Box M1 (FOXM1) Expression and Antitumor Effect of FOXM1 Inhibition in Angiosarcoma.

Authors:  Takamichi Ito; Kenichi Kohashi; Yuichi Yamada; Takeshi Iwasaki; Akira Maekawa; Masaaki Kuda; Daichi Hoshina; Riichiro Abe; Masutaka Furue; Yoshinao Oda
Journal:  J Cancer       Date:  2016-04-27       Impact factor: 4.207

3.  FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors.

Authors:  Franziska Briest; Erika Berg; Irina Grass; Helma Freitag; Daniel Kaemmerer; Florentine Lewens; Friederike Christen; Ruza Arsenic; Annelore Altendorf-Hofmann; Almut Kunze; Jörg Sänger; Thomas Knösel; Britta Siegmund; Michael Hummel; Patricia Grabowski
Journal:  Oncotarget       Date:  2015-04-10

4.  Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas.

Authors:  Akira Maekawa; Kenichi Kohashi; Masaaki Kuda; Kunio Iura; Takeaki Ishii; Makoto Endo; Tetsuya Nakatsura; Yukihide Iwamoto; Yoshinao Oda
Journal:  BMC Cancer       Date:  2016-07-20       Impact factor: 4.430

5.  Associations and prognostic significance of p27Kip1, Jab1 and Skp2 in non-Hodgkin lymphoma.

Authors:  Yan Ma; Meijuan Yan; Hua Huang; Li Zhang; Qian Wang; Yaqi Zhao; Jianmei Zhao
Journal:  Mol Clin Oncol       Date:  2016-08-10

6.  Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer.

Authors:  Sanaz Taromi; Florentine Lewens; Ruza Arsenic; Dagmar Sedding; Jörg Sänger; Almut Kunze; Markus Möbs; Joana Benecke; Helma Freitag; Friederike Christen; Daniel Kaemmerer; Amelie Lupp; Mareike Heilmann; Hedwig Lammert; Claus-Peter Schneider; Karen Richter; Michael Hummel; Britta Siegmund; Meike Burger; Franziska Briest; Patricia Grabowski
Journal:  Oncotarget       Date:  2017-09-23

Review 7.  The multifaceted roles of FOXM1 in pulmonary disease.

Authors:  Yumei Li; Feng Wu; Qi Tan; Mengfei Guo; Pei Ma; Xuan Wang; Shuai Zhang; Juanjuan Xu; Ping Luo; Yang Jin
Journal:  Cell Commun Signal       Date:  2019-04-16       Impact factor: 5.712

8.  Casticin induces ovarian cancer cell apoptosis by repressing FoxM1 through the activation of FOXO3a.

Authors:  Ling Jiang; Xiao-Cheng Cao; Jian-Guo Cao; Fei Liu; Mei-Fang Quan; Xi-Feng Sheng; Kai-Qun Ren
Journal:  Oncol Lett       Date:  2013-03-14       Impact factor: 2.967

9.  Expression of Forkhead box M1 in soft tissue leiomyosarcoma: Clinicopathologic and in vitro study using a newly established cell line.

Authors:  Akira Maekawa; Kenichi Kohashi; Nokitaka Setsu; Masaaki Kuda; Kunio Iura; Takeaki Ishii; Tomoya Matsunobu; Tetsuya Nakatsura; Yukihide Iwamoto; Yoshinao Oda
Journal:  Cancer Sci       Date:  2016-01-12       Impact factor: 6.716

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.